Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

The overall results of this study confirm the effectiveness of both IFX and ADA in achieving remission in patients with BS affected by mucocutaneous involvement.

Authors

Institutions

Publication Details

Journal
Annals of the Rheumatic Diseases
Published
2024-10-17
DOI
https://doi.org/10.1136/ard-2024-226113
Citations
12
Primary Topic
Ocular Diseases and Behçet’s Syndrome
Type
article
Field-Weighted Citation Impact
6.46

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

Maria Letizia Urban, Stefano Gentileschi, Marta Mosca, Emanuele Chiara et al.
12 citations
Annals of the Rheumatic Diseases
Ocular Diseases and Behçet’s Syndrome
6.46
article

Efficacy and safety of infliximab or adalimumab in severe mucocutaneous Behçet's syndrome refractory to traditional immunosuppressants: a 6-month, multicentre, randomised controlled, prospective, parallel group, single-blind trial

Maria Letizia Urban, Stefano Gentileschi, Marta Mosca, Emanuele Chiara, Ornella Della Casa Alberighi, Valentina Lorenzoni, Carlo Salvarani, Rosaria Talarico, Lorenzo Emmi, Matteo Piga, Irene Mattioli, Alberto Floris, Alberto Cauli, Federica Di Cianni, Diana Marinello, Nazzareno Italiano, Chiara Posarelli, Luca Cantarini, S. Vagnani, Giacomo Emmi, Gianni Andreozzi, Giuseppe Turchetti, Michele Figus, Claudia Fabiani, Stefano Bombardieri, Alessandra Bianco
article en
12 citations

Abstract

The overall results of this study confirm the effectiveness of both IFX and ADA in achieving remission in patients with BS affected by mucocutaneous involvement.

Annals of the Rheumatic DiseasesVol. 84(3)
University of Siena (IT), University of Pisa (IT), University of Modena and Reggio Emilia (IT), University of Trieste (IT), Scuola Superiore Sant'Anna (IT), University of Cagliari (IT), Monash Medical Centre (AU), Istituto Giannina Gaslini (IT), Azienda Sanitaria Unità Locale di Reggio Emilia (IT), Ospedale di Cattinara (IT), Ospedale Santa Maria alle Scotte (IT), Azienda Ospedaliera Universitaria Pisana (IT), University of Florence (IT), Monash University (AU)
Agenzia Italiana del Farmaco, Ministero della Salute
Good health and well-being
Openalex Percentile: Top 3%
Ocular Diseases and Behçet’s Syndrome
6.46
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.